<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123079</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-865-1002</org_study_id>
    <nct_id>NCT05123079</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants</brief_title>
  <official_title>A Randomized, 3-Period Crossover Trial to Evaluate the Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center trial in healthy participants. This is a crossover design,&#xD;
      open-label treatment trial with 3 periods, 6 sequences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label, randomized, 3-period, 6-sequence, crossover design to investigate&#xD;
      the relative bioavailability and effect of food on Darigabat.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 7, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1, single-center trial in healthy participants. The trial is an open-label, randomized, 3-period, 6-sequence, crossover design to investigate the relative bioavailability and effect of food of Darigabat from a single oral.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Dose: Peak Plasma Concentrations</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Peak Plasma Concentration (Cmax) for Darigabat under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose: Area under the plasma concentration-time curve</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) for Darigabat under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose: Area under the plasma concentration-time curve from time zero to last concentration measured</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to last concentration measured (AUClast) for Darigabat under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose: Time of Maximum Observed Plasma Concentrations</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Time of Maximum Observed Plasma Concentrations (Tmax) for Darigabat under fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Objective: Single Dose: Peak Plasma Concentrations</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Peak Plasma Concentration (Cmax) for Darigabat under fed and fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Objective: Single Dose: Area under the plasma concentration-time curve</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) for Darigabat under fed and fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Objective: Single Dose: Area under the plasma concentration-time curve from time zero to infinity</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-865 under fed and fasted conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Objective: Single Dose: Time of Maximum Observed Plasma Concentrations</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Time of Maximum Observed Plasma Concentrations (Tmax) for Darigabat under fasted and fed conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome (AE)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Number of subjects with reported Treatment Emergent Adverse Events (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome (ECGs)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Number of subjects with clinically significant changes in Electrocardiograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome (Labs)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Number of subjects with clinically significant changes in laboratory measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome (Vital Signs)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Number of subjects with clinically meaningful changes in vitals signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome (Physical/Neurological Exam)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Number of subjects with clinically significant changes in physical and neurological exams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome (C-SSRS)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Changes from baseline of the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent.&quot; The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Strength Tablet, Fasted (Without Food)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single High-Strength Tablet, Fed (With Food)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current Strength Tablets Fasted (Without Food)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darigabat</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Current Strength Tablets Fasted (Without Food)</arm_group_label>
    <arm_group_label>Single High-Strength Tablet, Fed (With Food)</arm_group_label>
    <arm_group_label>Single Strength Tablet, Fasted (Without Food)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women of nonchildbearing potential and men, ages 18 to 55 years, inclusive.&#xD;
&#xD;
          2. Healthy as determined by medical evaluation by the investigator.&#xD;
&#xD;
          3. Body mass index of 18.5 to 30.0 kg/m2, inclusive, and a total body weight &gt;50 kg (110&#xD;
             lbs).&#xD;
&#xD;
          4. A male participant with a pregnant or a nonpregnant partner of childbearing potential&#xD;
             must agree to use contraception.&#xD;
&#xD;
          5. Capable of giving signed informed consent and complying with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or past history of significant cardiovascular, pulmonary, gastrointestinal,&#xD;
             renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus),&#xD;
             malignancy (except for basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ, at the discretion of the investigator), hematological, immunological,&#xD;
             neurological, or psychiatric disease.&#xD;
&#xD;
          2. Serious risk of suicide in the opinion of the investigator.&#xD;
&#xD;
          3. History of substance or alcohol-use disorder (excluding nicotine or caffeine) within&#xD;
             12 months prior to signing the ICF.&#xD;
&#xD;
          4. Any condition that could possibly affect drug absorption.&#xD;
&#xD;
          5. Receipt of SARS-CoV2 vaccine or booster as follows:&#xD;
&#xD;
               -  mRNA: within 14 days prior to dosing&#xD;
&#xD;
               -  Non-mRNA: within 28 days prior to dosing&#xD;
&#xD;
          6. Have recently been diagnosed with symptomatic COVID-19 or test positive for COVID-19&#xD;
             within 30 days prior to signing the ICF.&#xD;
&#xD;
          7. Taking any prohibited medication prior to randomization or likely to require&#xD;
             prohibited concomitant therapy.&#xD;
&#xD;
          8. History of HIV, hepatitis B, or hepatitis C infection, or positive result for HIV,&#xD;
             hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody.&#xD;
&#xD;
          9. Positive drug screen (including nicotine and cannabinoids) or a positive test for&#xD;
             alcohol.&#xD;
&#xD;
         10. Abnormal clinical laboratory test results or vital measurements at Screening.&#xD;
&#xD;
         11. Any other abnormal safety findings unless, based on the investigator's judgment, the&#xD;
             findings are not medically significant and would not impact the safety of the&#xD;
             participant or the interpretation of the trial results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann M Dandurand, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cerevel Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Inc.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paige Ramirez</last_name>
      <phone>602-437-0097</phone>
      <phone_ext>66061</phone_ext>
      <email>paige.ramirez@celerion.com</email>
    </contact>
    <investigator>
      <last_name>Trisha Tavares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Food effect</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

